哈罗制药
HROW
27.28
-1.47
-5.11%
哈罗制药
US · HROW
#3155 按市值排名
27.28
-1.47
-5.11%
实时 - 追踪5344个代码 - 心跳于523秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例上升了0.2个百分点。
机构持股
- 机构持股比例
- 58.61% +0.16pp
- 机构数量
- 261 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund39.49%
Individual/Insider16.43%
Hedge Fund13.10%
VC/PE Fund2.61%
Private Company1.39%
Public Company1.11%
Government Pension Fund0.57%
Insurance Company0.22%
Family Office/Trust0.13%
Other24.97%
主要股东 截至 2026-05-14
Mark Baum
7.99% · 3.00M 股
BlackRock
7.31% · 2.74M 股
Opaleye Management Inc.
6.40% · 2.40M 股
Daniel Kaufman
5.01% · 1.88M 股
Vanguard Capital Management, LLC
4.41% · 1.65M 股
Private Capital Management, LLC
4.26% · 1.60M 股
Deep Track Capital, LP
2.58% · 969.00K 股
State Street Global Advisors
2.51% · 939.89K 股
Geode Capital Management, LLC
2.42% · 905.56K 股
Andrew Boll
2.17% · 814.68K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 32次买入 · 18次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Mark Baum | Chairperson & CEO | 7.99% |
| Andrew Boll | Chief Financial Officer | 2.17% |
| John Saharek | Chief Commercial Officer | 1.25% |
| Adrienne Graves | Director | 0.00% |
| Lauren Silvernail | Director | 0.00% |
| Opaleye Management Inc. | -- | -- |
| Amir Shojaei | Chief Scientific Officer | -- |
| Perry Sternberg | Independent Director | -- |
| Randall Pollard | Chief Accounting Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-13 | Amir Shojaei | Chief Scientific Officer | Derivative Exercise and Sale | -11,250 | $35.96–40.00 |
| 2026-06-17 | Adrienne Graves | Director | Other Derivative Acquisition | +5,248 | -- |
| 2026-06-17 | Lauren Silvernail | Director | Other Derivative Acquisition | +5,248 | -- |
| 2026-06-17 | Perry Sternberg | Independent Director | Other Derivative Acquisition | +5,248 | -- |
| 2026-05-17 | Adrienne Graves | Director | Open Market Acquisition | +1,000 | $31.07 |
| 2026-05-17 | Lauren Silvernail | Director | Open Market Acquisition | +1,000 | $31.00 |
| 2026-05-14 | Amir Shojaei | Chief Scientific Officer | Other Derivative Acquisition | +10,000 | -- |
| 2026-05-13 | Mark Baum | Chairperson & CEO | Open Market Acquisition | +10,000 | $30.20 |
| 2026-05-13 | Andrew Boll | Chief Financial Officer | Open Market Acquisition | +3,500 | $29.90 |
| 2026-03-03 | Opaleye Management Inc. | -- | Open Market Disposition | -198,572 | $39.15–39.67 |
| 2026-02-26 | Opaleye Management Inc. | -- | Open Market Disposition | -5,000 | $54.18 |
| 2026-01-05 | Opaleye Management Inc. | -- | Open Market Disposition | -20,000 | $53.35 |
| 2025-12-11 | Mark Baum | Chairperson & CEO | Derivative Exercise and Sale | -79,994 | $3.95–47.06 |
| 2025-12-11 | Mark Baum | Chairperson & CEO | Derivative Exercise and Retained | +100,006 | $3.95 |
| 2025-12-11 | Andrew Boll | Chief Financial Officer | Derivative Exercise and Sale | -26,665 | $3.95–47.06 |
| 2025-12-11 | Andrew Boll | Chief Financial Officer | Derivative Exercise and Retained | +33,335 | $3.95 |
| 2025-08-31 | Randall Pollard | Chief Accounting Officer | Other Derivative Acquisition | +30,000 | $39.00 |
| 2025-07-20 | Mark Baum | Chairperson & CEO | Derivative Exercise and Sale | -313,338 | $7.87–37.08 |
| 2025-07-20 | Mark Baum | Chairperson & CEO | Derivative Exercise and Retained | +286,662 | $7.87 |
| 2025-06-30 | Mark Baum | Chairperson & CEO | Other Derivative Acquisition | +889,500 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
哈罗制药 讨论区 0 条评论